Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 10Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Carcinoma, Renal Cell 7Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myeloproliferative Disorders 3Lung Neoplasms 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Neuroblastoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2

Interventions

pembrolizumab 24Paclitaxel 20Carboplatin 19Taxes 7temsirolimus 6Trastuzumab 6Topotecan 5Radiotherapy 5Cisplatin 5atezolizumab 4Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Gemcitabine 4Docetaxel 4Biopsy 4Bevacizumab 4olaparib 3lenvatinib 3dostarlimab 3Sirolimus 3Pemetrexed 3Irinotecan 3Interleukin-12 Subunit p35 3Fulvestrant 3Cetuximab 3Albumin-Bound Paclitaxel 3spartalizumab 2gedatolisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Endometrial Neoplasms × CTLA-4 Antigen × Clear all
NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡